Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067325 | 0.88 | ITGB3 (0.61) | POLBITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL5603960 | 0.88 | ITGB3 (0.61) | POLBITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL7622370 | 0.88 | ITGB3 (0.61) | POLBITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL8733191 | 0.88 | BIRC2 (0.44) | CA12CA9CA7CA14CA2 | |
| SCHEMBL22164251 | 0.86 | CA12 (0.55) | CA12CA9CA7CA14CA2 | |
| SCHEMBL22164250 | 0.86 | CA12 (0.55) | CA12CA9CA7CA14CA2 | |
| SCHEMBL8728179 | 0.84 | SIRT2 (0.47) | CA12CA9CA7CA14CA2 | |
| SCHEMBL5966640 | 0.84 | CA12 (0.61) | CA12CA9CA7CA14CA2 | |
| SCHEMBL5966638 | 0.84 | CA12 (0.61) | CA12CA9CA7CA14CA2 | |
| SCHEMBL7229783 | 0.84 | ITGB3 (0.54) | CA12CA9CA7CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311281-B1 | ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS | MIGENIX INC (CA) | 2007-10-24 | — | — | EP | disclosed |
| EP-1311281-A4 | ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS | MICROLOGIX BIOTECH INC (CA) | 2005-08-24 | — | — | EP | disclosed |
| US-6750199-B2 | SULFONYLATION CORE ANTIBIOTIC | MICROLOGIX BIOTECH INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| EP-1311281-A1 | ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 2003-05-21 | — | — | EP | disclosed |
| US-20020028771-A1 | Antimicrobial sulfonamide derivatives of lipopeptide antibiotics | BIOSOURCE PHARM, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2002005837-A1 | ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028771-A1 | Antimicrobial sulfonamide derivatives of lipopeptide antibiotics | STS, CUTA, LSS | CA12 3809/4885CA9 3299/4885CA7 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.